Choline

Choline

SCHEMBL868978

C[N+](C)(C)CCO.O=S(=O)(O)S

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2

The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
LMNA P02545 2/20 0.60
CYP3A4 P08684 1/20 0.60
SLC5A7 Q9GZV3 1/20 0.60
BBOX1 O75936 3/20 0.36
SLC6A4 P31645 1/20 0.36
ACHE P22303 2/20 0.32
GALR3 O60755 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ADRA2A P08913 1/20 0.31
ADRA1A P35348 1/20 0.31
PGR P06401 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
HTR1A P08908 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRM3 P20309 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Choline SCHEMBL393397 0.89 MEN1 (0.67) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL872579 0.86 MEN1 (0.63) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL27987657 0.86 LMNA (0.63) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL3790707 0.86 MEN1 (0.63) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL28318708 0.84 CYP3A4 (0.68) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL339064 0.84 MEN1 (0.60) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL2459166 0.84 MEN1 (0.60) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL27779128 0.84 MEN1 (0.60) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL31591121 0.83 MEN1 (0.67) MEN1KMT2ALMNACYP3A4SLC5A7
Choline SCHEMBL872577 0.82 MEN1 (0.57) MEN1KMT2ALMNACYP3A4SLC5A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150174160-A1 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES PRAVDA JAY (US) 2015-06-25 US claimed
EP-2866565-A2 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES Pravda, Jay (US) 2015-05-06 EP claimed
US-20140335205-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS THERAPEUTIC RES LLC (US) 2014-11-13 US claimed
WO-2014008273-A2 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES PRAVDA JAY (US) 2014-01-09 WO claimed
US-20120322773-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS PRAVDA JAY (US) 2012-12-20 US claimed
US-20100112088-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS PRAVDA JAY 2010-05-06 US claimed
US-10064877-B2 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress THERAPEUTIC RESEARCH, LLC (US) 2018-09-04 US disclosed
US-20170296559-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS THERAPEUTIC RES LLC (US) 2017-10-19 US disclosed
US-20170182067-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS THERAPEUTIC RES LLC (US) 2017-06-29 US disclosed
US-9511049-B2 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress THERAPEUTIC RESEARCH LLC (US) 2016-12-06 US disclosed
US-20150174160-A1 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES PRAVDA JAY (US) 2015-06-25 US disclosed
EP-2866565-A2 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES Pravda, Jay (US) 2015-05-06 EP disclosed
US-20150105356-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS THERAPEUTIC RESEARCH LLC (US) 2015-04-16 US disclosed
EP-2392321-A1 Combined composition for rectal administration for the treatment of inflammatory bowel disease Pravda, Jay (US) 2011-12-07 EP disclosed
EP-2162125-B1 Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease PRAVDA JAY (US) 2011-10-19 EP disclosed
US-20100184728-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS THERAPEUTIC RESEARCH LLC (US) 2010-07-22 US disclosed
US-20100112088-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS PRAVDA JAY 2010-05-06 US disclosed
EP-2162125-A2 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS Pravda, Jay (US) 2010-03-17 EP disclosed
WO-2008156671-A2 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS PRAVDA JAY (US) 2008-12-24 WO disclosed
US-7312243-B1 Materials and methods for treatment of gastrointestinal disorders THERAPEUTIC RESEARCH, LLC 2007-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10064877-B2 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress NR3C1, GSTA1, LTC4S MEN1 4754/4885KMT2A 3870/4885LMNA 3822/4885
US-20100184728-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS NR3C1, GSTA1, LTC4S MEN1 4754/4885KMT2A 3870/4885LMNA 3822/4885
US-20120322773-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS LPO, ALOX15B, ALOX15 MEN1 3706/4885KMT2A 721/4885LMNA 1762/4885
US-20170296559-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS NR3C1, GSTA1, LTC4S MEN1 4754/4885KMT2A 3870/4885LMNA 3822/4885
US-20150105356-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS NR3C1, GSTA1, LTC4S MEN1 4754/4885KMT2A 3870/4885LMNA 3822/4885
US-20140335205-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS TXN, GPX4, TXN2 MEN1 4690/4885KMT2A 3479/4885LMNA 4303/4885
US-20100112088-A1 MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS TXN, GPX4, TXN2 MEN1 4690/4885KMT2A 3479/4885LMNA 4303/4885
US-20150174160-A1 METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES OAT, OTC, HOGA1 MEN1 3440/4885KMT2A 4117/4885LMNA 3265/4885
US-20170182067-A1 MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS NR3C1, GSTA1, LTC4S MEN1 4754/4885KMT2A 3870/4885LMNA 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.